• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

BerGenBio

Selective AXL inhibitors

  • About BerGenBio
    • About BerGenBio
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline overview
    • bemcentinib | NSCLC
    • bemcentinib | COVID-19
    • bemcentinib | Melanoma
    • bemcentinib | AML
    • BGB149
    • BGB601
    • Discovery
    • Publications
    • Expanded access policy
  • Media Centre
    • News
    • Events
    • COVID-19 Media Pack
    • Media Contacts
  • Investors
    • Share Information
    • Largest Shareholders
    • Stock Exchange Notices
    • Presentations
    • Financial Reports
    • Financial Calendar
    • Analysts
    • General Meetings
    • Corporate Governance
    • IR Contacts
  • Careers
  • Contact
Home  /  2019

Year: 2019

202020192018201720162015

BERGENBIO PRESENTS PRELIMINARY CLINICAL DATA FROM PHASE II COMBINATION TRIAL OF BEMCENTINIB AND LDAC IN ELDERLY AML PATIENTS AT ASH 2019

December 9, 2019

Phase II trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC)  in elderly AML patients…

Read More

BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER 2019

November 19, 2019

FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML)High Impact oral presentation of…

Read More

BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019

November 7, 2019

Bergen, Norway, 7 November 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BerGenBio’s bemcentinib meets primary endpoint in first cohort of phase 2 NSCLC study in combination with Keytruda ®

November 6, 2019

Primary endpoint, Overall Response Rate, has been met in predominantly PD-L1 negative/low patientsSecondary endpoint, median…

Read More

BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib

October 23, 2019

Bergen, Norway 22nd October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BerGenBio to Present clinical data from Phase II trial with selective AXL inhibitor at 34th Annual SITC Meeting

October 15, 2019

Bergen, Norway, 02 October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 5
  • NEXT

Primary Sidebar

  • Media Centre
  • News
  • Events
  • COVID-19 Media Pack
  • Media Contacts

News Subscription

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email.

We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.

Footer

Key Information

  • Pipeline
  • Investors
  • News
  • Presentations
  • Management Team

Useful Information

  • Privacy Policy
  • Terms of Use
  • Job Applicant Privacy Notice
  • Site Map

Get In Touch

BerGenBio ASA
Company registration number 992 219 688

Jonas Lies vei 91, 5009 Bergen, Norway

www.bergenbio.com

+ 47 559 61 159

Copyright © 2017 BerGenBio ASA. All right reserved. Designed by Utopian Designs